Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
Biomeasure, Inc. Patents
Assignee:
Biomeasure, Inc.
Address:
Milford, MA
No. of patents:
37
Patents:












Patent Number Title Of Patent Date Issued
6150333 Methods of using a somatostatin analogue November 21, 2000
The present invention is directed to a method of treating one or more of the following disease and/or conditions, which comprises administering to a patient in need thereof the compound H-.beta.-D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH.sub.2, where the Cysteines are bonded by a disulfi
6087337 Method for treating benign and malignant proliferative skin disease July 11, 2000
A method of treating a mammal suffering from benign or malignant proliferative skin disease, e.g., melanoma or malignant skin metastases of melanoma, by topically administering to the mammal at the site of said diseased skin an effective amount of a somatostatin analog containing six
6083915 Method for treating liver cancer July 4, 2000
A method of treating liver cancer involving administration to the subject a therapeutically effective amount of a bombesin analog.
6001801 Cyclic peptide analogs of somatostatin December 14, 1999
A cyclic peptide analog of somatostatin wherein a disulfide bond links the N-terminus residue and the C-terminus residue.
5969095 Analogs of parathyroid hormone October 19, 1999
Peptide variants of fragment (1-34) of parathyroid hormone, in which at least one of the amino acid residues at positions 7, 11, 23, 24, 27, 28, and 31 is cyclohexylalanine, or at least one of the amino acid residues at positions 3, 16, 17, 18, 19, and 34 is .alpha.-aminoisobutyric acid;
5877277 Octapeptide bombesin analogs March 2, 1999
A linear (i.e., non-cyclic) analog of biologically active amphibian bombesin, mammalian gastrin-releasing peptide (GRP), or mammalian growth hormone releasing factor (GRF), having an active site and a binding site responsible for the binding of the peptide to a receptor on a target cell.
5767236 Linear therapeutic peptides June 16, 1998
The invention features linear therapeutic peptides of the following formula: ##STR1## in which A.sup.1 is a D-.alpha.-aromatic amino acid or a D-.alpha.-tethered amino acid; A.sup.2 is Gln, His, 1-methyl-His, or 3-methyl-His; A.sup.3 is the D- or L-isomer selected from Nal, Trp,
5750646 Bradykinin analogs with non-peptide bond May 12, 1998
A linear peptide which is an analog of a naturally occurring, biologically active peptide having an active site and a binding site responsible for the binding of the peptide to a receptor on a target cell, cleavage of a peptide bond in the active site to the naturally occurring peptide b
5739110 Protection of hemopoietic cells April 14, 1998
A method of promoting regeneration of hemopoietic cells in a subject undergoing chemotherapy or radiotherapy, which method includes the steps of (i) administering to the subject a first amount of AcSDKP or an agonist thereof, the first amount being effective to reduce the proliferation o
5736517 Treatment of cancer with peptides April 7, 1998
A method of treating cancer in a human patient, the method involving administering to the patient a cancer cell inhibiting amount of an analog of a naturally occurring biologically active peptide or a fragment thereof, the peptide being one of mammalian gastrin-releasing peptide, neu
5723577 Analogs of parathyroid hormone March 3, 1998
Peptide variants of fragment (1-34) of parathyroid hormone, in which at least one of the amino acid residues at positions 7, 11, 23, 24, 27, 28, and 31 is cyclohexylalanine, or at least one of the amino acid residues at positions 3, 16, 17, 18, 19, and 34 is .alpha.-aminoisobutyric acid;
5663295 Opioid peptides September 2, 1997
Opioid peptides including those of the formula ##STR1## in which A.sub.1 is the identifying group of an amino acid selected from 3,4-dihydroxyphenylalanine, 3,4-dimethoxyphenylalanine, azatyrosine, and 2,6-dimethyltyrosine; A.sub.2 is the identifying group of an amino acid select
5569741 Cyclic octapeptide neuromedin B receptor antagonists October 29, 1996
A cyclic octapeptide of the formula: ##STR1## wherein: A.sup.1 is D-Nal or D-Trp;A.sup.3 is Phe, F.sub.5 -Phe, or X-Phe wherein X is a halogen, NO.sub.2, CH.sub.3, or OH;A.sup.5 is --NH--CH(Y)--CO-- wherein Y is (CH.sub.2).sub.m --R.sub.4 --N(R.sub.5)(R.sub.6) or (CH.sub.2).sub.n --R
5552520 Therapeutic peptide derivatives September 3, 1996
Peptide derivatives containing one or more substituents separately linked by an amide, amino or sulfonamide bond to an amino group on either the N-terminal end or side chain of a biologically active peptide moiety. The peptide derivatives have relatively enhanced biological activity when
5504069 Inhibition of trauma-induced tumor growth April 2, 1996
A method for inhibiting in a mammal the accelerated growth of a solid primary or metastatic tumor resulting from tissue trauma caused surgically, non-surgically, or by tissue ulceration, which method comprises the step of administering to the mammal a therapeutically effective amount
5462926 Neuromedin B receptor antagonists which demonstrate selectivity October 31, 1995
A method of selectively inhibiting biochemical activity of cells induced by neuromedin B. The method includes the step of contacting cells which contain neuromedin B receptor with a cyclic octapeptide, D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Nal-NH.sub.2, or an analog thereof.
5411943 Hepatoma treatment with somatostatin analogs May 2, 1995
A method for treating liver cancer in a mammalian subject. The method includes administering to the subject a composition which contains a therapeutically effective amount of an octapeptide of the following formula: ##STR1## wherein, A.sub.1 is D-.beta.-Nal or D-Phe; A.sub.2 is P
5217955 Treatment of cancer with peptide analog of bombesin, GRP, litorin or neuromedin June 8, 1993
A method of treating cancer in a human patient, the method involving administering to the patient a cancer cell inhibiting amount of an analog of a naturally occurring biologically active peptide or a fragment thereof, the peptide being one of mammalian gastrin-releasing peptide, neu
5091381 2H-1,3,4-benzotriazepin-2-ones February 25, 1992
Peripheral benzodiazepines (BZDs) are useful in treating disorders caused by abnormal level of peripheral benzodiazepene receptor activity and having, in one aspect, the formula: ##STR1## wherein each X, X.sub.1, X.sub.2, X.sub.3, X.sub.4, X.sub.5, X.sub.6, and X.sub.8, independe
5084555 An octapeptide bombesin analog January 28, 1992
A linear (i.e., non-cyclic) analog of biologically active amphibian bombesin, mammalian gastrin-releasing peptide (GRP), or mammalian growth hormone releasing factor (GRF), having an active site and a binding site responsible for the binding of the peptide to a receptor on a target cell.
5084443 Promoting expression of acetylcholine receptors with LHRH antagonist January 28, 1992
A method for promoting regrowth of damaged nerve tissue in a mammal, the method comprising administering to the mammal a nerve tissue regrowth promoting amount of an LHRH antagonist namely, N-Acetyl -D-Naphthylalanine-D-para-Cl-Phe-D-Phe-Ser-Tyr-D-Arg-Phe-Arg-Pro-D-Ala-NH. sub.2.
5073541 Treatment of small cell lung cancer with somatostatin analogs December 17, 1991
A method of treating a mammal suffering from cancer by administering to the mammal somatostatin or an analog thereof, the analog being a hexapeptide analog or higher, in a dosage of at least 25 .mu.g/kg/day.
5010089 CCK antagonists and their use in treating gastrointestinal disorders April 23, 1991
In general, the invention features compounds having the formula: ##STR1## or a pharmaceutically acceptable salt thereof, wherein AR is an indolyl, quinolyl, naphthyl or a mono- or di- R.sup.1 substituted naphthyl in which R.sup.1 is, independently, an alkyl group having 1-5, inclusiv
4983567 Immunomodulators and methods of making same January 8, 1991
A compound having the formula: ##STR1## or a pharmaceutically acceptable salt thereof, wherein A is an amino acid identifying group; B is a hydrogen atom, an alkyl group having 1-5, inclusive, carbon atoms, or an aralkyl group having 6-12, inclusive, carbon atoms; carbon atom 2 i
4957915 Benzodiazepine analogs September 18, 1990
BZDs of the general formula 1: ##STR1## where: R represents H, alkyl, alkenyl, cycloalkyl or cycloalkenyl each with up to 8 carbon atoms, phenylalkyl with an alkylene chain of 1 to 3 carbon atoms and optionally substituted on the phenyl radical with one or two substituents select
4902708 CCK antagonists February 20, 1990
In general, the invention features compounds having the formula ##STR1## or a pharmaceutically acceptable salt thereof, wherein each R.sup.1 is, independently, an alkyl group having 1-5, inclusive, carbon atoms, an alkoxy group having 1-5, inclusive, carbon atoms, a halogen, amino,
4894231 Therapeutic agent delivery system January 16, 1990
A therapeutic agent delivery system that includes a biodegradable polymer and a therapeutic agent, the delivery system being coated with a barrier substance that decreases the quantity of the agent released from the system, compared to the quantity of the agent released from a system not
4871870 Immunomodulators and method of making same October 3, 1989
A compound having the formula ##STR1## or a pharmaceutically acceptable salt thereof, wherein A is an amino acid identifying group; B is a hydrogen atom, an alkyl group having 1-5, inclusive, carbon atoms, or an aralkyl group having 6-12, inclusive, carbon atoms; carbon atom 2 is
4814463 CCK antagonists March 21, 1989
In general, the invention features CCK antagonist compounds having the formula: ##STR1## or a pharmaceutically acceptable salt thereof, wherein each R.sup.1 is, independently, an alkyl group having 1 to 5, inclusive, carbon atoms, an alkoxy group having 1 to 5, inclusive, carbon
4785003 N-disubstituted glycine and B-amino-propionic acid derivatives having anti-ulcer activity November 15, 1988
A compound having the formula ##STR1## or a pharmaceutically acceptable salt thereof, wherein A is N-AC-Sar, pGlu, or homo-pGlu-; B is an aryl group, a heteroaryl group, a cycloalkyl group, an aralkyl group, a heteroalkyl group, a heteroaralkyl group, a benzoyl group, an alkyl gr
4734414 Anti-inflammatory and anti-arthritic pyrazolo-[1,5-a]-1,3,5-triazine derivatives, compositions, March 29, 1988
The invention features compounds having anti-arthritic activity and having the formula ##STR1## wherein X is an alkyl group having between 1 and 8, inclusive, carbon atoms and Y is a hydroxyalkylamino group having between 2 and 8, inclusive, carbon atoms; a dialkylamino group hav
4652668 Aromatic amino acid derivatives March 24, 1987
A compound having the formula: ##STR1## wherein n is 0-5, inclusive; R.sub.1 is H or the identifying group of an amino acid; and R.sub.2 is H, aralkyl, or alkyl.
4625026 2-amino-4-oxo-tricyclicpyrimidines having antiviral activities against herpes simplex virus type November 25, 1986
In one aspect, compounds having antiviral activity and having the general formula: ##STR1## wherein each R.sup.2, independently, is H or lower (fewer than 6 carbon atoms) alkyl; each R.sup.3, independently, is H or lower alkyl R.sup.0 is H or lower alkyl, R.sup.1 is H or lower al
4598067 Antiulcer compounds July 1, 1986
A compound having the formula ##STR1## or a pharmaceutically acceptable salt thereof, wherein A is N--Ac--Sar, pGlu, or homo-pGlu-; B is an aryl group, a heteroaryl group, a cycloalkyl group, an aralkyl group, a heteroalkyl group, a heteroaralkyl group, a benzoyl group, an alkyl
4565815 Pyrazolo[1,5-a]-1,3,5-triazines January 21, 1986
A compound having anti-ulcer activity and having the formula ##STR1## wherein D is H, SH, NH.sub.2, OH, R.sup.4 S where R.sup.4 is a lower alkyl group; E is OH or NH.sub.2 ; J is H or aryl; X is CH or N; Y is CH, N, or CT, wherein T is a halogen; Z is CH or N; A is ##STR2## a
4496540 Therapeutic compounds January 29, 1985
In one aspect, compounds capable of inhibiting an endopeptidase responsible for a degradation pathway of enkephalin and having the general formulawherein A is one of the aromatic group-containing amino acid residues L-tryptophyl, D-tryptophyl, L-tyrosyl, D-tyrosyl, L-phenylalanyl, or D-p
4495193 Imidazole compounds which reduce gastric acid secretion January 22, 1985
A compound having gastric acid secretion reducing activity and having the formula ##STR1## wherein each V and W, independently, is H, --CH.sub.2 COOR.sup.4 where R.sup.4 is H or lower alkyl, --CH.sub.2 CN, or ##STR2## or V and W together represent .dbd.CHCOOR.sup.4 or .dbd.CH

 
 
  Recently Added Patents
Signal activated molecular delivery
Denial of service (DoS) attack prevention through random access channel resource reallocation
User interfaces
Method for producing purified influenza virus antigen
Scanning optical positioning system with spatially triangulating receivers
System and method for providing advertising content using a group training system
5-HT.sub.3 receptor modulators, methods of making, and use thereof
  Randomly Featured Patents
Electrochromic layer and devices comprising same
Bridged bi-aromatic ligands, catalysts, processes for polymerizing and polymers therefrom
Method of forming threaded polar openings for composite pressure vessels
Reshaping device for optical short pulses
Insulated water heater for hydrotherapy baths, spas, and skid packs
Method of using diazotype photographic materials with preexposure treatment to form uniform sites of refractive index change
Boosted air source heat pump
Method of forming cartridge chambers in firearm barrels
Continuous crystallization system with controlled nucleation for milk fat fractionation
Paper embossing system with a flexible counter and method of embossing